Skip to main content

Dr. John O. Schorge, MD

Gynecologic Oncology (Gynecologic Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
33
In the NPI registry since
2006
Medicare patients seen, 2024
13

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1993Medical school: Vanderbilt University School of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Gynecologic Oncology Physician primary
    MA license 153463 · NH license 14268
  • Obstetrics Physician
    TN license 64958

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Gynecologic Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
13
Services billed
25
Patients’ average age
69

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Payments from drug and device companies

In 2025, 9 companies reported 22 payments worth $4,704 in total to this clinician.

By company
Intuitive Surgical, Inc.$3,419
Medtronic, Inc.$516
Coopersurgical, Inc.$207
Dilon Technologies, Inc.$146
Eisai Inc.$143
Biotissue Holdings Inc.$124
Ethicon US, LLC$97.03
Corcept Therapeutics$26.43
By type
Travel and Lodging$1,788
Education$1,500
Food and Beverage$1,416

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jun 25, 2025Intuitive Surgical, Inc.
Jun 25, 2025
Education
DAVINCI XI · SURGERY · in-kind
$1,500
May 22, 2025Intuitive Surgical, Inc.
May 22, 2025
Travel and Lodging
Da Vinci Surgical System · SURGERY · travel to COLUMBUS, OH · in-kind
$540
Apr 9, 2025Intuitive Surgical, Inc.
Apr 9, 2025
Travel and Lodging
Da Vinci Surgical System · SURGERY · travel to COLUMBUS, OH · in-kind
$525
Apr 23, 2025Intuitive Surgical, Inc.
Apr 23, 2025
Travel and Lodging
Da Vinci Surgical System · SURGERY · travel to COLUMBUS, OH · in-kind
$353
Apr 24, 2025Intuitive Surgical, Inc.
Apr 24, 2025
Travel and Lodging
Da Vinci Surgical System · SURGERY · travel to COLUMBUS, OH · in-kind
$160
Apr 25, 2025Intuitive Surgical, Inc.
Apr 25, 2025
Travel and Lodging
Da Vinci Surgical System · SURGERY · travel to COLUMBUS, OH · in-kind
$160
Apr 9, 2025Intuitive Surgical, Inc.
Apr 9, 2025
Travel and Lodging
Da Vinci Surgical System · SURGERY · travel to COLUMBUS, OH · in-kind
$30.00
May 22, 2025Intuitive Surgical, Inc.
May 22, 2025
Travel and Lodging
Da Vinci Surgical System · SURGERY · travel to COLUMBUS, OH · in-kind
$19.00

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Tennessee →

Industry-funded research

Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $23,209 in research payments for these studies, mostly to the institutions running them.

  • PSR - Surgical
    Medtronic, Inc.
  • A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
    Karyopharm Therapeutics Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Gynecologic Oncology clinicians in Memphis

Sources

NPI registry (CMS NPPES, November 2026; record last updated June 21, 2022), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1669439923. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.